Clinical Trials
14 trialsNCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT03804255 2026-05-06
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Eastern Cooperative Oncology Group
Withdrawn
NCT07092410 2026-04-21
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Withdrawn
NCT04064424 2026-04-20
Cancer Prevention & Online Technologies
Stanford University
Phase NA Withdrawn
NCT03382704 2026-01-16
Vellus Hair Loss as a Marker for Peri-ocular Malignancy
NHS Lothian
Withdrawn
NCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT01861938 2025-10-02
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
Phase 2/3 Withdrawn
NCT05717140 2025-08-07
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
Phase 1 Withdrawn
NCT06508827 2025-07-09
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Phase 2 Withdrawn
NCT05106192 2025-06-12
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT04099446 2025-06-05
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
ProgenaBiome
Withdrawn
NCT06190249 2025-06-05
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Case Comprehensive Cancer Center
Phase 1 Withdrawn